HSE advisers to discuss weight-loss drug reimbursement
Ireland’s Health Service Executive is due to consider reimbursement for weight-loss medication at an expert drugs group meeting on Tuesday, according to The Irish Times in a report published on 12 October 2026. Saxenda remains the only GLP-1 treatment reimbursed by the HSE for weight loss in Ireland.
The discussion concerns whether access through public funding can be widened in a market where patients may otherwise face substantial monthly charges. It is not an announcement that another medicine has been approved for reimbursement.
There is an important uncertainty in the account. The Irish Times does not unambiguously identify which medicine is on Tuesday’s agenda: its discussion moves from Ozempic to a pricing offer from Eli Lilly, the manufacturer of Mounjaro. The report therefore cannot establish precisely which product the group will consider.
The financial stakes are considerable. Professor Michael Barry, who leads the National Centre for Pharmacoeconomics, has warned that the treatment discussed in connection with Lilly’s offer could cost the state between €2 billion and €3 billion over five years, even after a substantial price reduction.
Saxenda and Ozempic have different HSE funding routes
Saxenda is injected daily. For weight-loss treatment, it is available without charge under the medical card scheme or subsidised through the Drugs Payment Scheme, which limits covered monthly expenditure to €80, according to the report.
Ozempic has a different position. The HSE confirmed that more than 45,000 people receive it without charge through the Long-Term Illness Scheme, while another 8,348 receive it under the medical card scheme. Both routes cover its use for type 2 diabetes, not weight loss.
Ozempic is not available under the Drugs Payment Scheme, The Irish Times reports. People can buy it privately for weight-loss purposes, but the reported cost exceeds €200 a month. The distinction between obtaining a prescription and having its cost covered is therefore central to understanding access.
The medicines are not interchangeable simply because they are discussed together. Novo Nordisk makes Ozempic and Wegovy, both of which contain semaglutide. Eli Lilly’s Mounjaro contains tirzepatide and is administered as a weekly injection.
For public reimbursement, the NCPE examines evidence of effectiveness alongside price and the likely impact on patients. Its assessment informs the HSE drugs group, which then makes recommendations to senior HSE management. An assessment or committee discussion is consequently one stage in a wider decision-making process.
Cost-effectiveness and affordability also answer different questions. A treatment may offer sufficient health benefit for its price yet still require a very large allocation of public money if many people qualify. The Irish Times reports that Ireland’s total medicines budget is expected to exceed €4 billion in 2027.
NCPE chief describes the limits of a manufacturer discount
The report cites a December 2025 NCPE assessment that found the treatment under consideration was not cost-effective at the assessed price. The centre nevertheless advised that reimbursement should be considered if a price reduction could be agreed with the manufacturer.
Barry said earlier in 2026 that Lilly had offered a significant reduction which could make the treatment cost-effective, or close to that threshold. His five-year spending estimate shows why an improved price would not, by itself, settle the funding question.
The potential benefits extend beyond the number on the scales. The Irish Times notes that some studies have indicated benefits involving cardiovascular risk, kidney disease progression and sleep apnoea. Such findings require attention to the particular medicine and condition studied, as explored in our coverage of GLP-1 medicines beyond weight loss.
Safety remains part of the assessment. Ireland’s Health Products Regulatory Authority said it had received more than 1,500 reports of suspected adverse reactions involving weight-loss medicines since 2023. Suspected reaction reports do not, on their own, establish causation or show how frequently a problem occurs among users. The need for clinical follow-up is also examined in our coverage of monitoring during Mounjaro treatment.
HSE eligibility rules and a funding decision remain outstanding
Tuesday’s discussion will feed into the HSE’s reimbursement process. The source gives no date for a final funding decision, no agreed price and no timetable for patients to receive any newly reimbursed treatment.
Access would depend on clinical criteria rather than an unrestricted entitlement. The report says clinicians would discuss eligibility with patients, typically taking account of BMI, obesity-related conditions, lifestyle and diet. It does not provide final thresholds for any expansion.
For patients awaiting a change, the unresolved questions are therefore specific: which medicine will be funded, for which patients, through which scheme and from what date. A favourable assessment of value would still need to be followed by a reimbursement decision and published access arrangements.
